MicroRNAs (miRNAs) 
Introduction

MicroRNAs (miRNAs) are non-coding RNAs 19-24 nucleotides (nt) long that down-regulate gene expression by regulating the translation and degradation of target mRNAs, through base pairing to complementary sites. This binding can be perfect in plants and partial in mammals [1, 2]. The discovery of miRNAs casts doubt on the 'central dogma' that genetic information flows directly from DNA to protein, where RNAs only serve as mediators. The first miRNA, discovered in the nematode Caenorhabditis elegans in 1993, is lin-4, which contains antisense sequences complementary to a repeated sequence element in the 3' untranslated region (UTR) of the lin-14
mRNA [3] . Further studies demonstrated that the lin-4 gene product was a noncoding RNA that regulated several critical genes during development at the post-transcriptional level [4] . Several years later, let-7 was discovered as another small regulatory RNA in C. elegans, which regulates the expression of many genes that control developmental timing and cellular differentiation [5] .
The biogenesis of miRNAs is divided between the nucleus and the cytoplasm. MiRNAs are initially transcribed by RNA polymerase II to produce long primary miRNAs (pri-miRNAs) [6] . Like protein-coding mRNAs, pri-miRNAs can be spliced, capped by 7-methyl guanosine at the 5' end, and have a polyadenylated tail added to the 3' end [7] . The human RNase III Drosha cleaves the pri-miRNA hairpin-shaped stem-loop structure to produce the precursor of miRNA (pre-miRNA) about 70-100 nt long with an extended stem-loop structure [8] . The pre-miRNAs are then transported to the cytoplasm by exportin-5 (Exp5)/RanGTP [9] . Once in the cytoplasm, pre-miRNAs are processed further by Dicer, a second RNase III endonuclease to produce the 19-24 nt miRNA duplexes [10] . To mediate the degradation or translation inhibition of target mRNAs, one strand of the duplex is incorporated into the protein effector complex miRISC (miRNA-containing RNA induced silencing complex) [11] .
Almost 50% of mammalian miRNA genes are located in introns of protein-encoding genes or long noncoding RNA (ncRNA) genes, while the remaining miRNA genes are independent transcription units with specific promoter core elements and polyadenylation signals [2, 12] . Approximately half of known miRNAs are found in clusters, and are transcribed as polycistronic primary transcripts [13] . MiRNAs [20] . Ramkissoon and colleagues [21] [23] . As activation of c-KIT occurs in diverse neoplasias [24] , and constitutive activation of c-KIT receptor tyrosine kinase prevents AML blasts from developing into normal blasts [25] [27] . Moreover, expression of miR-223 is not limited to granulocytic differentiation but has been reported in erythroid cells [28] . [30] . HOXB8 is activated transcriptionally in AML cells to prevent differentiation of factor-dependent myeloid progenitors [31] . [32] . [34] . [25] . MiR-155 and its non-coding RNA host gene BIC are up-regulated 100-fold in Burkitt's lymphoma patients [35] [42] ). Prognosis is poor for the majority of AML patients, and, after 25 years of research, the standard therapy for AML is highly toxic and poorly tolerated (for review see [43] ).
Human monocyte/macrophage differentiation is regulated by miR-424, miR-17-5p, miR-20a and miR-106a. The expression of miR-424 is up-regulated by PU.1, a transcriptional factor specific to the monocytic lineage. Elevated miR-424 targets nuclear factor-A (NFI-A) mRNA to repress its translation. Since decreased NFI-A expression is required for the activation of differentiation-specific genes, these three components coordinate to designate monocytic differentiation of precursor cells [33]. Another mechanism regulating monocytopoiesis includes miR-17-5p, -20a and -106a, the multipotent transcriptional factor AML1 and macrophage colonystimulating factor (M-CSF) receptor (M-CSFR). The three miRNAs target AML1 and down-regulated its expression, which promotes M-CSFR gene transcription, resulting in enhanced blast proliferation and inhibition of monocytic differentiation and maturation
Some miRNAs, although not directly involve in leukemogenesis, function in the development of normal blood cells by a mechanism that suggests a possible pathological function. MiR-155 and miR-451 are key regulators of normal erythroid differentiation. Functional studies using both gain-of-function and loss-offunction approaches in murine erythroleukemia (MEL) cells showed that miR-451 is associated with erythroid maturation
In an earlier study Shakti and colleagues [44] [45] [46] [47] also revealed their potential connection to leukemia [48] . A distinct correlation of these miRNAs with the HOX genes was reported, which exhibited an elevated expression in leukemogenesis [49] [25, 36] . Therefore, miR-142 is a promising regulator in the pathogenesis of myelogenous malignancies. [58] , activate mitogenic signaling, degrade inhibitory proteins [59] and prevent or compensate for apoptosis (for review see [60] ).
MiRNAs in chronic myeloid leukemia
Philadelphia (Ph) chromosome was first reported in 1960 as a chromosomal abnormality associated with a specific type of leukemia (CML) [54]. The Ph chromosome is the result of a t(9;22) reciprocal chromosomal translocation that involves the Abl proto-oncogene normally on chromosome 9 and Bcr on chromosome 22 [55, 56]. The deregulated ABL tyrosine kinase activity is the pathogenetic principle [57]. Clinically, chronic-phase CML is not a severe problem until the disease progresses to acceleration and blast crisis, often within 5 years of diagnosis. The fusion protein BCR-ABL participates in diverse signal transduction pathways to decrease adhesion of CML cells to bone marrow stromal cells as well as the extracellular matrix
The expression of miRNAs is regulated by a variety of proteins, especially the proteins involved in tumorigenesis. The miR-17-92 cluster, comprised of miR-17, miR-18a, miR-19a, miR-20a, miR19b-1 and miR-92-1, is located in chromosome 13, a region that is amplified in human B-cell lymphomas, and is a known oncogene in mouse Burkitt's lymphoma [61]. The miR-17-92 cluster is an important CML-associated oncogene. The polycistronic primiRNA transcript is up-regulated in CML but increased mature miRNAs are only detected in early chronic-phase but not in blastcrisis CML [62]. Overexpression of the miR-17-92 cluster in K562, a CML cell line, promotes cell proliferation. In addition, the overexpression also compensates for the cell cycle arrest induced by c-MYC silencing. SL3-3 provirus integration near the gene that encodes the miR-17-92 cistron can induce T-cell lymphoma.
Insertion of the retroviral enhancers probably caused an increase in expression of the primary transcript, consequently increasing the concentration of the oncogenic miRNA [63] .
The expression of the miR-17-92 cluster can be regulated by three members of the E2 transcription factor family (E2F1-3) [64] . In turn, miR-17 and miR-20 target E2F1 in a negative feedback loop [65] . Nevertheless Effective ATRA treatment of AML involves miRNA regulation [72] . While human myeloid leukemia cells with normal RA receptors have virtually no response to ATRA, myeloid leukemia cells with dominant negative RARs have a therapeutic response to this agent [73] . The active RARs serve as transcription factors, regulating the expression of a growing number of genes, such as c-myc, p21 and Hox family members [74] [75] [76] [77] .
All-trans retinoic acid (ATRA) is regularly used for the treatment of APL. The dramatic therapeutic activity of ATRA is due to induction of terminal granulocytic differentiation in the malignant promyelocytes [67-69]. Promyelocytic leukemia (PML)/RA receptor ␣ (RAR␣), a characteristic fusion protein of APL chromosomal translocation t(15;17) [70], blocks the differentiation and neoplastic transformation of APL blasts by disrupting the function of PML and repressing transcription of genes regulated by RAR␣ at the physiological level [71]. Increased doses of RA can overcome this block and induce terminal differentiation of PML/RAR␣-positive APL blasts both in vitro and in vivo
The relationship between ATRA treatment and miRNA expression was first reported by Nadia and colleagues [23] . [78] [79] [80] , it can down-regulate c-myc expression [81] and can be down-regulated by the formation of AML1-ETO fusion protein [82] . Recently, more miRNAs that are up-regulated during ATRA-induced granulocytic differentiation in APL patients and cell lines were found [83] , among which are miR-15a, miR-16-1, let-7a, let-7d [37] . [64, 66] [84] 
After the APL cell line is treated with ATRA, C/EBP␣, instead of NFI-A, binds to the promoter of the miR-223 gene and up-regulates miR-223 expression. MiR-223 mediates translational repression of the NFI-A mRNA, thereby decreasing the NFI-A protein expression, forming a regulatory circuit that controls granulocyte differentiation. While C/EBP␣ has critical roles in the differentiation of bipotential myeloid progenitors to granulocytes
Sometimes, several transcription factors bind to the same regulatory site, and their relationship can be either competitive, such as binding of C/EBP␣ or NFI-A to the promoter of miR-223 gene [23], or cooperative, such as c-MYC and E2F family members regulating the expression of the miR-17-92 gene cluster
. In contrast to the role of miR-221 and miR-222 in myeloid differentiation, studies in cutaneous melanoma identified the promyelocytic leukemia zinc finger (PLZF) transcription factor as a repressor of miR-221 and miR-222, by binding directly to their putative regulatory region. This repression down-regulates miR-221 and miR-222 expression, thereby leading to enhanced proliferation and differentiation blockade of the melanoma cells
Epigenetic mechanisms silence miRNA gene expression
In normal eukaryotic cells, DNA methylation and histone acetylation interplay for maintaining the equilibrium, allowing temporal expression of some genes [86, 87] . In neoplastic cells, this balance is frequently disrupted. In leukemic cells, CpG islands in the promoter region of genes critical for cell cycle progression and maturation are frequently hypermethylated [88] , and DNA methyltransferases (DNMTs) are often overexpressed. These findings are paralleled by transcriptional repression of downstream genes [89] , including miRNA genes. A putative AML1 binding site at the 5' end of the predicted core promoting sequence on the pre-miR-223 upstream region has been identified using computational search methods [90] . The AML1-ETO oncoprotein may bind at this site to regulate transcription [91] . The AML1-ETO fusion protein is found in t (8;21) [94, 95] . These studies suggest improved prognosis of patients treated with such enzyme inhibitors.
Post-transcriptional regulation of miRNA expression
The expression of a large fraction of miRNAs can also be regulated during the Drosha processing step. This regulation has a major impact on mature miRNA production during embryonic development and in cancer [96] . In cancer samples, the correlation between mature miRNAs and the abundance of their primary transcripts is unknown, which suggests that the Drosha processing step is disrupted in cancer. [39] ) that focus on pathophysiological events critical for leukemogenesis, such as unbridled proliferation, failure to differentiate, stromal cell-mediated survival factors, and failure to undergo normal programmed cell death.
Discussion and perspectives
